Compare · ABT vs PLYX
ABT vs PLYX
Side-by-side comparison of Abbott Laboratories (ABT) and Polaryx Therapeutics Inc. (PLYX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and PLYX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $185.36B, about 1698.0x PLYX ($109.2M).
- PLYX has been more active in the news (5 items in the past 4 weeks vs 4 for ABT).
- ABT has more recent analyst coverage (25 ratings vs 2 for PLYX).
- Company
- Abbott Laboratories
- Polaryx Therapeutics Inc.
- Price
- -
- -
- Market cap
- $185.36B
- $109.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 4
- 5
- Recent ratings
- 25
- 2
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- SEC Form 10-Q filed by Abbott Laboratories
- FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
- Abbott Laboratories filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Roman Michael F
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- EXECUTIVE VICE PRESIDENT Morrone Louis H. covered exercise/tax liability with 269 units of Common shares without par value, decreasing direct ownership by 0.35% to 76,574 units (SEC Form 4)
Latest PLYX
- SEC Form DEFA14A filed by Polaryx Therapeutics Inc.
- SEC Form DEF 14A filed by Polaryx Therapeutics Inc.
- SEC Form S-8 filed by Polaryx Therapeutics Inc.
- Polaryx Therapeutics Inc. filed SEC Form 8-K: Leadership Update
- Polaryx Therapeutics Inc. filed SEC Form 8-K: Shareholder Director Nominations, Other Events
- H.C. Wainwright initiated coverage on Polaryx Therapeutics with a new price target
- Chief Executive Officer Yang Alex Keun Mo bought $360,004 worth of shares (88,453 units at $4.07) (SEC Form 4)
- Polaryx Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits
- Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial
- Polaryx Therapeutics Receives GHP Magazine's Healthcare & Pharmaceuticals Awards